WO2003066806A3 - Therapeutic use of aziridino compounds - Google Patents

Therapeutic use of aziridino compounds Download PDF

Info

Publication number
WO2003066806A3
WO2003066806A3 PCT/US2002/035501 US0235501W WO03066806A3 WO 2003066806 A3 WO2003066806 A3 WO 2003066806A3 US 0235501 W US0235501 W US 0235501W WO 03066806 A3 WO03066806 A3 WO 03066806A3
Authority
WO
WIPO (PCT)
Prior art keywords
aziridino compounds
therapeutic use
aziridino
compounds
treatment
Prior art date
Application number
PCT/US2002/035501
Other languages
French (fr)
Other versions
WO2003066806A2 (en
Inventor
John Chapman
Bernadette Alford
Andrei A Purmal
Boris Zavizion
Original Assignee
Vi Technologies Inc
John Chapman
Bernadette Alford
Andrei A Purmal
Boris Zavizion
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2001/049956 external-priority patent/WO2002055095A2/en
Application filed by Vi Technologies Inc, John Chapman, Bernadette Alford, Andrei A Purmal, Boris Zavizion filed Critical Vi Technologies Inc
Priority to EP02806003A priority Critical patent/EP1451308A4/en
Priority to JP2003566157A priority patent/JP2005517023A/en
Priority to AU2002366446A priority patent/AU2002366446A1/en
Priority to CA002466251A priority patent/CA2466251A1/en
Publication of WO2003066806A2 publication Critical patent/WO2003066806A2/en
Publication of WO2003066806A3 publication Critical patent/WO2003066806A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/396—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having three-membered rings, e.g. aziridine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Methods are provided for treatment of diseases. The methods include preventing or inhibiting transcription and/or replication of a nucleic acid molecule by administering to a subject in need of such treatment an effective amount of one or more aziridino compounds. Pharmaceutical compositions comprising the one or more aziridino compounds also are provided.
PCT/US2002/035501 2001-11-06 2002-11-05 Therapeutic use of aziridino compounds WO2003066806A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP02806003A EP1451308A4 (en) 2001-11-06 2002-11-05 Therapeutic use of aziridino compounds
JP2003566157A JP2005517023A (en) 2001-11-06 2002-11-05 Therapeutic use of aziridine compounds
AU2002366446A AU2002366446A1 (en) 2001-11-06 2002-11-05 Therapeutic use of aziridino compounds
CA002466251A CA2466251A1 (en) 2001-11-06 2002-11-05 Therapeutic use of aziridino compounds

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
PCT/US2001/049956 WO2002055095A2 (en) 2000-11-06 2001-11-06 Use of aziridino-compounds in the treatment of immune dysfunctions
USPCT/US01/49956 2001-11-06
US36564802P 2002-03-18 2002-03-18
US60/365,648 2002-03-18
US37918802P 2002-05-09 2002-05-09
US60/379,188 2002-05-09

Publications (2)

Publication Number Publication Date
WO2003066806A2 WO2003066806A2 (en) 2003-08-14
WO2003066806A3 true WO2003066806A3 (en) 2003-12-24

Family

ID=27738963

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/035501 WO2003066806A2 (en) 2001-11-06 2002-11-05 Therapeutic use of aziridino compounds

Country Status (5)

Country Link
EP (1) EP1451308A4 (en)
JP (1) JP2005517023A (en)
AU (1) AU2002366446A1 (en)
CA (1) CA2466251A1 (en)
WO (1) WO2003066806A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040053208A1 (en) * 1995-08-29 2004-03-18 V. I. TECHNOLOGIES, Inc. Methods to selectively inactivate parasites in biological compositions
WO2009149081A1 (en) 2008-06-02 2009-12-10 Novelmed Therapeutics, Inc. Method for treating inflammatory conditions

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6093564A (en) * 1997-10-03 2000-07-25 V.I. Technologies, Inc. Methods and compositions for the selective modification of nucleic acids
US6136586A (en) * 1995-08-29 2000-10-24 Vi Technologies, Inc. Methods for the selective modification of viral nucleic acids

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0419890A3 (en) * 1989-09-29 1991-05-29 American Cyanamid Company Stable pharmaceutical formulations for antineoplastic compounds having more than one ethyleneimine group, and method
US6114108A (en) * 1995-08-29 2000-09-05 V.I. Technologies, Inc. Methods and compositions for the selective modification of viral nucleic acids
US20030149011A1 (en) * 2000-11-06 2003-08-07 Samuel Ackerman Methods and reagents for extracorporeal immunomodulatory therapy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136586A (en) * 1995-08-29 2000-10-24 Vi Technologies, Inc. Methods for the selective modification of viral nucleic acids
US6093564A (en) * 1997-10-03 2000-07-25 V.I. Technologies, Inc. Methods and compositions for the selective modification of nucleic acids

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1451308A4 *

Also Published As

Publication number Publication date
EP1451308A4 (en) 2004-11-17
AU2002366446A1 (en) 2003-09-02
WO2003066806A2 (en) 2003-08-14
EP1451308A2 (en) 2004-09-01
CA2466251A1 (en) 2003-08-14
JP2005517023A (en) 2005-06-09

Similar Documents

Publication Publication Date Title
NO324227B1 (en) Cyclopropyl-fused pyrrolidine-based compounds, pharmaceutical compositions and combinations containing them as well as the use thereof for the manufacture of medicaments for the treatment of diseases
WO2002042462A3 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
WO2001090091A8 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO2004006858A3 (en) Compounds, compositions, and methods employing same
BR0214343A (en) 11 - Beta - Hydroxy Steroid Dehydrogenase Inhibitors Type 1
WO2008022256A3 (en) Methods and compositions for preventing or treating age-related diseases
MXPA04004842A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1.
MXPA04004837A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1.
IL157656A (en) Metalloproteinase inhibitors, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for the treatment of diseases mediated by metalloproteinase enzymes
NO340679B1 (en) Pyridazine derivatives, pharmaceutical compositions comprising such and such compounds and preparations for use in therapeutically active substances for the treatment and prevention of diseases
HK1080459A1 (en) Novel pyrimidineamide derivatives and the use thereof
WO2004055006A8 (en) Novel compounds having selective inhibiting effect at gsk3
CA2427227A1 (en) Lactam compound
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
MY148125A (en) Compounds
WO2005058233A3 (en) Methods for treatment of acute pancreatitis
WO2005037798A3 (en) Amide or thiomide derivatives and their use in the treatment of pain
WO2002040702A3 (en) Methods for the treatment of cancer and other diseases and methods of developing the same
BRPI0410049A (en) compound or a pharmaceutically acceptable salt or stereoisomer thereof, use of a compound, pharmaceutical composition, and pharmaceutical kit
WO2005014572A8 (en) Pyrimidylpyrrole derivatives active as kinase inhibitors
CA2433833A1 (en) Use of flumazenil in developing a drug for the treatment of alcohol dependence
WO2004014367A3 (en) Use of an amyloid beta vaccination in combination with a selective cox-2 inhibitor for the treatment of alzheimer's disease
WO2004073615A8 (en) Deazaflavin compounds and methods of use thereof
WO2001062799A3 (en) Method for inhibiting angiogenesis using molecules that enhance plasmin activity
BR0310061A (en) Methods for treating respiratory diseases and conditions with a selective inhibitor of inos and a inhibitor of pde and their compositions

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2466251

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002366446

Country of ref document: AU

Ref document number: 2003566157

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002806003

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002806003

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2002806003

Country of ref document: EP